We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Marinus Pharmaceuticals Inc (MRNS) USD0.001

Sell:$0.29 Buy:$0.31 Change: $0.0656 (25.51%)
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$0.29
Buy:$0.31
Change: $0.0656 (25.51%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$0.29
Buy:$0.31
Change: $0.0656 (25.51%)
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The Company is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). It is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.

Contact details

Address:
5 Radnor Corporate Center Suite 500
100 Matsonford Rd
RADNOR
19087
United States
Telephone:
+1 (484) 8014670
Website:
https://marinuspharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MRNS
ISIN:
US56854Q2003
Market cap:
$14.19 million
Shares in issue:
55.19 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Scott Braunstein
    Chairman of the Board, President, Chief Executive Officer
  • Steven Pfanstiel
    Chief Financial Officer, Chief Operating Officer, Treasurer
  • Martha Manning
    Senior Vice President, General Counsel, Corporate Secretary
  • Joseph Hulihan
    Chief Medical Officer
  • Christina Shafer
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.